The new tower will be home of the Dan L Duncan Comprehensive Cancer Center. Photo courtesy of Baylor College of Medicine

Anew structure aimed at greatly expanding medical services and outpatient care to residents of Greater Houston recently topped off.

At an official ceremony attended by VIPs and industry names, Baylor St. Luke's Medical Center toasted the completion of the concrete structure pivotal in the construction of the O'Quinn Medical Tower at the McNair Campus.

This new 12-story O'Quinn Medical Tower at Baylor St. Luke's - McNair Campus will be the new clinical home for the Dan L Duncan Comprehensive Cancer Center, per a release. The center is nationally ranked for cancer care by U.S. News & World Report and is one of only three National Cancer Institute-designated comprehensive cancer centers in Texas. It earned that designation through Baylor College of Medicine.

Additionally, the O'Quinn Medical Tower is part of the expanding McNair Campus. This campus promises more than 400,000 square feet of space to support and provide personalized care to patients and families, including another hospital bed tower and ambulatory care center, press materials describe.

Those familiar with the area will recognize that the campus sits directly adjacent to the planned site of TMC3, a new 37-acre campus that will be located between Old Spanish Trail and Brays Bayou.

"The new O'Quinn Tower and its designation as the clinical home of Baylor's Dan L Duncan Comprehensive Cancer Center will be an important milestones in Baylor's mission," said Dr. Paul Klotman, president, CEO and executive dean of Baylor College of Medicine, in a release. "The McNair Campus is the hub of our clinical activity, and we look forward to the continued expansion."

------

This article originally ran on CultureMap.

Health care leaders joined a virtual panel to discuss the effects of COVID-19 and more. Photo by Dwight C. Andrews/Greater Houston Convention and Visitors Bureau

Overheard: Houston health care experts sound off on how tech and COVID-19 have affected the industry

eavesdropping in houston

There has been an undeniable paradigm shift in the health care industry due to COVID-19 as well as the growth of technology. A group of professionals sat down to discuss what in particular has changed for the industry as a whole as well as at local institutions.

At a panel for Venture Houston, a two-day conference put on by the HX Venture Fund on February 4th and 5th, a few health care professionals weighed in on all the changes to the industry for the startups, investors, corporations, and more who attended the virtual event. Here are some significant overheard moments from the virtual panel — Thinking Past a COVID World.

“For most of health care, this last year has been probably five years of rapid cycle re-innovation and movement forward — particularly in the digital realm.”

Marc Boom, president and CEO of Houston Methodist. From rapid adoption of telemedicine to developing a COVID-19 vaccine in less than a year, health care has seen rapid growth. However, there's fine tuning still needed, Boom continues.

"At the end of the day there's only so much we can do virtually," he adds.

“The most incredible thing was how the vaccines got developed so quickly.”

Chris Rizik, CEO of Renaissance Venture Partners. A large portion of the industry wasn't excited about RNA vaccines, but the COVID-19 vaccines might have changed some minds. It took 11 months to get it out into the world, but 10 of that was purely regulatory, he adds.

"One of the sustaining changes of the COVID-19 pandemic is I think RNA vaccines are here to stay."

​— Paul Klotman, executive dean of Baylor College of Medicine. Klotman adds that the vaccine's trials were so impressively quick because there were just so many COVID patients sick and eligible to enroll.

“I think one of the things the TMC institutions did really well was to decide really early on was to share data.”

Boom says, adding that the TMC represents around 70 percent of Houston's adults and around 90 percent of the city's pediatric patients. This opportunity for data is "one of the most robust sources of real-time data."

"Yes, you're going to compete clinically, but there's a lot of collaboration to be done especially during a pandemic," Boom says of the TMC's member organizations prioritizing collaboration with data sharing.

“Houston has done better than almost all major metropolitan areas because we have came together as a city and a community.”

Klotman says, adding that the vast patient base the TMC is key.

"There's a huge opportunity here for early biotech development," he says. "Because there are so many patients, there are huge opportunities to do new trials."

“The real challenge is for investors to be in tune to know what’s here to stay, and to invest around that."

Rizik says, adding that 2020 was the biggest year for health care investment with more money going into deals, rather than more deals occuring.

“We’re seeing a huge uptick in people interested in health professions, thanks to COVID.”

Boom says of the industry's workforce, which has usually been hard to recruit and grow.

“The medical school communities are all racing to change the way we teach and the kind of information we teach.”

Klotman says of the future of the workforce.

“Unlike most industries, technology is tended to be cumbersome in health care.

​— Boom says adding that new technology means added costs and slowed down processes that can't replace the human touch. Houston Methodist is looking for innovations that don't take health care professionals away from patients.

“If there’s anything this last year has shown us is that as fast as we thought we were going, we need to go faster. We’re excited to work with companies with great ideas.”

— Boom says of the future of tech in health care. "I think we're on a very transformational era in digital health right now — but there's a lot of work to be done still."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Austin company to bring AI-powered school to The Woodlands

AI education

Austin-based Alpha School, which operates AI-powered private schools, is opening its first Houston-area location in The Woodlands.

The 8,000-square-foot school, scheduled to be ready for the 2026-27 academic year, initially will serve students in kindergarten through eighth grade. Alpha says the school will offer “open workshop spaces and innovative classrooms that support personalized instruction, core academics, leadership development, and real-world life skills.”

Alpha sets aside two hours each school day for the AI-driven, self-paced study of core subjects like math, reading and science. The rest of each school day consists of life-skills workshops focusing on topics such as leadership and financial literacy.

Alpha’s school in The Woodlands has begun accepting applications for the 2026-27 school year. Annual tuition costs $40,000.

“The Woodlands is one of the most dynamic, forward-thinking communities in Texas, and Alpha is proud to bring

an innovative educational model that complements its strong academic foundation,” says Rachel Goodlad, head

of expansion for Alpha.

Founded in 2014, Alpha School combines adaptive technology-driven instruction with immersive life-skills workshops. Its model emphasizes mastery-based learning in core subjects alongside development of communication, critical thinking, financial literacy and leadership skills. It operates more than 15 schools across the country.

Elsewhere in Texas, Alpha operates schools in Austin, Brownsville, Fort Worth and Plano. Alpha also operates 12 Texas Sports Academy campuses in Texas, including locations in Houston, Pearland and Richmond, along with a NextGen Academy esports school in Austin, a school for gifted students in Georgetown, and lower-cost Nova Academy campuses in Austin and Bastrop.

Alpha has fans and critics. While supporters tout students’ high achievement rates, detractors complain about the high tuition and the AI-influenced depersonalization of education.

“Students and our country need to be in relationship with other human beings,” Randi Weingarten, president of the American Federation of Teachers, a teachers union, tells The New York Times. “When you have a school that is strictly AI, it is violating that core precept of the human endeavor and of education.”

Alpha co-founder MacKenzie Price, a podcaster and social media influencer, doesn’t share Weingarten’s views.

“Parents and teachers: We need to embrace this change,” Price wrote after President Trump signed an executive order promoting AI in schools.

The Times notes that Alpha doesn’t employ AI as a tutor or a supplement. Rather, the newspaper says, AI is “the school’s primary educational driver to move students through academic content.”

Houston researcher secures $1.7M to develop drug for aggressive form of breast cancer

cancer research

A University of Houston researcher has joined a $3.2 million effort to develop a new drug designed to attack a cancer-driving protein commonly found in triple-negative breast cancer.

Triple-negative breast cancer (TNBC) is one of the most difficult-to-treat forms of cancer and accounts for 10 percent to 15 percent of all breast cancer cases. The disease gets its name because tumors associated with it test negative for estrogen receptors, progesterone receptors and excess HER2 protein, making it difficult to target. Due to this, TNBC is often treated with general chemotherapy, which can come with negative side effects and drug resistance, according to UH.

UH College of Pharmacy research associate professor Wei Wang is developing a drug that can target the disease more specifically. The drug will target MDM2, a protein often overproduced in TNBC that also contributes to faster tumor growth.

Wang is working on a team led by Wei Li, director of the University of Tennessee Health Science Center College of Pharmacy’s Drug Discovery Center. She has received $1.7 million to support the research.

Wang and UH professor of pharmacology and toxicology Ruiwen Zhang have discovered a compound that can break down MDM2. In early laboratory models, the compound has shown the ability to shrink tumors.

Wang and Zhang will focus on understanding how the treatment works and monitoring its effectiveness in models that closely mirror human disease.

“We will study how the drug targets MDM2 and evaluate the most promising drug candidates to determine effective dosing, understand how the drug behaves in the body, compare it with existing treatments and assess early safety,” Wang said in a news release.

Li’s team at the University of Tennessee will be working on the chemistry and drug design end of the project.

“This work could lead to an entirely new class of therapies for triple-negative breast cancer,” Li added in the release. “We’re hopeful that by directly removing the MDM2 protein from cancer cells, we can help more patients respond to treatment regardless of their tumor type.”